How two industry leaders are advancing ‘organ-on-a-chip’ models to accelerate novel approaches in medicine

Molecular Devices and MIMETAS have partnered to develop, image and gain insights from organ-on-a-chip models that shed light on promising new therapies, including (anti-)angiogenesis-based medicine. The ability to accurately predict how a drug candidate will affect the human body, both in its therapeutic efficacy and potential toxicity, is a central aim in drug development. Strategies to improve the accuracy of the prediction and a shift to earlier detection during the development of drug candidates can significantly reduce the time and cost of bringing a drug to market. And while there’s still a long way to go, researchers are making remarkable...